^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Triplex (CMV-MVA vaccine)

    i
    Other names: CMV-MVA vaccine, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, CMV-MVA triplex vaccine
    Associations

    News

    Trials
    Company:
    Fortress
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    3ms
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jul 2025 --> Jun 2026
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    6ms
    A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P1, N=46, Not yet recruiting, City of Hope Medical Center
    New P1 trial
    |
    Triplex (CMV-MVA vaccine)
    8ms
    CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Aug 2025
    Trial completion date
    |
    Triplex (CMV-MVA vaccine)
    9ms
    Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=15, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Trial completion date: May 2028 --> Mar 2029 | Trial primary completion date: May 2028 --> Mar 2029
    Enrollment open • Trial completion date • Trial primary completion date
    |
    CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    9ms
    CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P2, N=216, Recruiting, City of Hope Medical Center | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2027 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    10ms
    Multi-antigen CMV-MVA Triplex Vaccine in Reducing CMV Complications in Patients Previously Infected With CMV and Undergoing Donor Hematopoietic Cell Transplant (clinicaltrials.gov)
    P2, N=102, Active, not recruiting, City of Hope Medical Center | Trial completion date: Dec 2024 --> Jul 2025
    Trial completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    12ms
    Allogeneic CMV-Specific CD19-CAR T Cells Plus CMV-MVA Triplex Vaccine After Matched Related Donor Hematopoietic Cell Transplant for the Treatment of Patients With High-Risk Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P1, N=15, Not yet recruiting, City of Hope Medical Center
    New P1 trial • CAR T-Cell Therapy • Triplex vaccine
    |
    CMV/CD19 bi-Specific CAR T • Triplex (CMV-MVA vaccine)
    1year
    Triplex Vaccine in Preventing CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplantation (clinicaltrials.gov)
    P2, N=7, Active, not recruiting, City of Hope Medical Center | N=12 --> 7
    Enrollment change • Triplex vaccine
    |
    Triplex (CMV-MVA vaccine)
    1year
    Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Treating Pediatric Patients With Positive Cytomegalovirus Undergoing Donor Stem Cell Transplant (clinicaltrials.gov)
    P1/2, N=80, Recruiting, City of Hope Medical Center | Trial completion date: Nov 2024 --> Dec 2026 | Trial primary completion date: Nov 2024 --> Dec 2026
    Trial completion date • Trial primary completion date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)
    over1year
    IRB 19065 - CMV-MVA Triplex Vaccine After Letermovir in HCT Recipients (clinicaltrials.gov)
    P=N/A, N=136, Not yet recruiting, City of Hope Medical Center
    New trial • Triplex vaccine
    |
    Triplex (CMV-MVA vaccine)
    over1year
    CMV-MVA Triplex Vaccination of Stem Cell Donors in Preventing CMV Viremia in Participants With Allogeneic Transplant (clinicaltrials.gov)
    P1, N=34, Active, not recruiting, City of Hope Medical Center | Trial completion date: Jun 2024 --> Dec 2024
    Trial completion date
    |
    Triplex (CMV-MVA vaccine)
    over1year
    CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant (clinicaltrials.gov)
    P2, N=216, Recruiting, City of Hope Medical Center | Initiation date: Apr 2024 --> Aug 2024
    Trial initiation date
    |
    HLA-DRB1 (Major Histocompatibility Complex, Class II, DR Beta 1)
    |
    Triplex (CMV-MVA vaccine)